SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50: 3.59 µM). SPP-037 exhibits anti-MDA-MB-231 cell migration activity by inhibiting integrin alpha2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used in breast cancer research[1].
Molekulargewicht:
736.31
Formel:
C36H50ClN3O9S
Target-Kategorie:
Endogenous Metabolite,FAK
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten